
1. Biol Blood Marrow Transplant. 2018 Sep;24(9):1814-1822. doi:
10.1016/j.bbmt.2018.05.018. Epub 2018 May 29.

A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous
Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on
1038 Patients From Fondazione Italiana Linfomi.

Olivieri J(1), Mosna F(2), Pelosini M(3), Fama A(4), Rattotti S(5), Giannoccaro
M(6), Carli G(7), Tisi MC(7), Ferrero S(8), Sgherza N(9), Mazzone AM(10), Marino 
D(11), Calimeri T(12), Loseto G(13), Saraceni F(14), Tomei G(15), Sica S(16),
Perali G(17), Codeluppi K(4), Billio A(2), Olivieri A(18), Orciuolo E(3), Matera 
R(6), Stefani PM(19), Borghero C(7), Ghione P(8), Cascavilla N(9), Lanza F(14),
Chiusolo P(16), Finotto S(11), Federici I(18), Gherlinzoni F(19), Centurioni
R(20), Fanin R(21), Zaja F(21); Fondazione Italiana Linfomi Postgraduate Master
Course.

Author information: 
(1)Clinica Ematologica, Centro Trapianti e Terapie Cellulari "C. Melzi," Azienda 
Sanitaria Universitaria Integrata di Udine, Udine, Italy; UOC Medicina Interna ed
Ematologia, Azienda Sanitaria Unica Regionale Marche AV3, Civitanova Marche,
Italy. Electronic address: jacopo.olivieri@hotmail.it.
(2)UOC di Ematologia e Centro Trapianto di Midollo Osseo, Ospedale Centrale "San 
Maurizio," Azienda Sanitaria dell'Alto Adige, Bolzano, Italy.
(3)Clinical and Experimental Medicine, Section of Hematology, University of Pisa,
Pisa, Italy.
(4)Ematologia, Arcispedale S. Maria Nuova, IRCCS Azienda Ospedaliera di Reggio
Emilia, Reggio Emilia, Italy.
(5)Department of Haematology Oncology, Fondazione IRCCS Policlinico San Matteo,
Pavia, Italy.
(6)Unità Operativa di Ematologia e Trapianto di cellule staminali, Presidio
Ospedaliero "Vito Fazzi", Lecce, Italy.
(7)Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy.
(8)Ematologia 1, Dipartimento di Biotecnologie Molecolari e Scienze per la
Salute, Università di Torino-AOU Città della Salute e della Scienza di Torino,
Turin, Italy.
(9)Ematologia, IRCCS Ospedale Casa Sollievo Sofferenza, San Giovanni Rotondo,
Italy.
(10)SC Ematologia, Ospedale "S. Giuseppe Moscati," Taranto, Italy.
(11)Oncologia Medica 1, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.
(12)Divisione di Ematologia, IRCCS Ospedale San Raffaele, Milano, Italy.
(13)Ematologia, IRCCS Ospedale Oncologico di Bari, Bari, Italy.
(14)Hematology and Stem Cell Transplant, Ravenna Hospital, Ravenna, Italy.
(15)Ematologia, Ospedale di Ivrea ASL TO4, Ivrea, Italy.
(16)Istituto di Ematologia, Università Cattolica del Sacro Cuore, Roma, Italy.
(17)Clinica Ematologica, Centro Trapianti e Terapie Cellulari "C. Melzi," Azienda
Sanitaria Universitaria Integrata di Udine, Udine, Italy.
(18)Clinica di Ematologia, Azienda Ospedaliera "Ospedali Riuniti," Ancona, Italy.
(19)U.O.C. di Ematologia, Dipartimento di Medicina Specialistica, Unità Locale
Socio-Sanitaria della Marca Trevigiana, Treviso, Italy.
(20)UOC Medicina Interna ed Ematologia, Azienda Sanitaria Unica Regionale Marche 
AV3, Civitanova Marche, Italy.
(21)Clinica Ematologica, Centro Trapianti e Terapie Cellulari "C. Melzi,"
Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Italy.

BEAM (carmustine [bis-chloroethylnitrosourea
(BCNU)]-etoposide-cytarabine-melphalan) chemotherapy is the standard conditioning
regimen for autologous stem cell transplantation (ASCT) in lymphomas. Owing to
BCNU shortages, many centers switched to fotemustine-substituted BEAM (FEAM),
lacking proof of equivalence. We conducted a retrospective cohort study in 18
Italian centers to compare the safety and efficacy of BEAM and FEAM regimens for 
ASCT in lymphomas performed from 2008 to 2015. We enrolled 1038 patients (BEAM
= 607, FEAM = 431), of which 27% had Hodgkin lymphoma (HL), 14% indolent
non-Hodgkin lymphoma (NHL), and 59% aggressive NHL. Baseline characteristics
including age, sex, stage, B-symptoms, extranodal involvement, previous
treatments, response before ASCT, and overall conditioning intensity were well
balanced between BEAM and FEAM; notable exceptions were median ASCT year
(BEAM = 2011 versus FEAM = 2013, P < .001), Sorror score ≥3 (BEAM = 15% versus
FEAM = 10%, P = .017), and radiotherapy use (BEAM = 18% versus FEAM = 10%,
P < .001). FEAM conditioning resulted in higher rates of gastrointestinal and
infectious toxicities, including severe oral mucositis grade ≥3 (BEAM = 31%
versus FEAM = 44%, P < .001), and sepsis from Gram-negative bacteria (mean
isolates/patient: BEAM = .1 versus FEAM = .19, P < .001). Response status at day 
100 post-ASCT (overall response: BEAM = 91% versus FEAM = 88%, P = .42), 2-year
overall survival (83.9%; 95% confidence interval [CI], 81.5% to 86.1%) and
progression-free survival (70.3%; 95% CI, 67.4% to 73.1%) were not different in
the two groups. Mortality from infection was higher in the FEAM group (subhazard 
ratio, 1.99; 95% CI, 1.02 to 3.88; P = .04). BEAM and FEAM do not appear
different in terms of survival and disease control. However, due to concerns of
higher toxicity, fotemustine substitution in BEAM does not seem justified, if not
for easier supply.

Copyright © 2018 The American Society for Blood and Marrow Transplantation.
Published by Elsevier Inc. All rights reserved.

DOI: 10.1016/j.bbmt.2018.05.018 
PMID: 29857196  [Indexed for MEDLINE]

